Healthcare Equipment and Supplies
Company Overview of Sequenom Center for Molecular Medicine, LLC
Sequenom Center for Molecular Medicine, LLC develops a range of molecular genetic laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. The company offers MaterniT21 PLUS test for fetal aneuploidies that analyzes the relative amount of 21, 18, 13, X and Y chromosomal material in circulating cell-free DNA from a maternal blood sample; Heredi-T cystic fibrosis carrier screen test that detects a phenotypically-confirmed panel selected from the John Hopkins CFTR2 database; SensiGene fetal RHD genotyping test for the analysis of fetal RHD genotype; and RetnaGene AMD test for age-related macular degeneration. Its laboratory tests provide early patient management i...
301 Michigan Street NE
Grand Rapids, MI 49503
Key Executives for Sequenom Center for Molecular Medicine, LLC
Vice President of National Accounts & Payor Strategies
Laboratory Director and Executive Director
Vice President and General Manager
Compensation as of Fiscal Year 2013.
Sequenom Center for Molecular Medicine, LLC Key Developments
Sequenom Center for Molecular Medicine Launches the Enhanced Sequencing Series for the MaterniT21(TM) PLUS Test
Oct 22 13
Sequenom Center for Molecular Medicine has launched the Enhanced Sequencing Series for its MaterniT21(TM) PLUS laboratory-developed test (LDT). The MaterniT21 PLUS test will begin reporting additional findings for the presence of subchromosomal microdeletions and autosomal trisomies for chromosomes 16 and 22, in addition to the previously announced additional findings for sex chromosome aneuploidies involving an abnormal number of the X or Y chromosomes. These additional findings complement the MaterniT21 PLUS test core identification of trisomies for chromosome 21, chromosome 18 and chromosome 13. With this expansion, the MaterniT21 PLUS test is the first-of-its-kind noninvasive prenatal technology (NIPT) to provide these comprehensive results from a maternal blood draw. Sequenom Laboratories will begin reporting on these select, clinically relevant microdeletions, including 22q11.2 deletion syndrome, Cri-du-chat syndrome, Prader-Willi/Angelman syndrome, 1p36 deletion syndrome, as well as trisomies 16 and 22 the last week of October. Results from a method validation study demonstrated high performance of the MaterniT21 PLUS test in accurately detecting these autosomal trisomies and select microdeletions.
Sequenom Center for Molecular Medicine, LLC and CombiMatrix Corporation Enters into Collaboration Agreement to Market Chromosomal Microarray Analysis for Prenatal Testing
Aug 1 13
Sequenom Inc. and CombiMatrix Corporation announced that the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to broaden and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients. Under the agreement, the two laboratories will collaboratively use their respective marketing channels and sales forces to promote the use of NIPT and CMA and work together to provide technical training to physicians and counseling, education and support services to physicians and their patients. The two companies plan to provide, when clinically appropriate, a comprehensive test result report for ordering physicians. Sequenom is a global leader in the NIPT market, and Sequenom CMM, its wholly owned subsidiary laboratory, developed the MaterniT21(TM) PLUS laboratory-developed test (LDT), a widely-ordered, noninvasive prenatal testing service for fetal chromosomal abnormalities. CombiMatrix is one of the few independent laboratories that specialize in CMA, the primary genetic test to evaluate newborns with birth defects that is now being more widely used for prenatal testing.
Sequenom Inc. and Sequenom Center for Molecular Medicine Announce License and Marketing Agreements with Laboratoire Cerba in France
May 30 13
Sequenom Inc. announced that it, along with its wholly owned subsidiary, Sequenom Center for Molecular Medicine has entered into technology licensing and marketing agreements with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. These agreements will expand access to Sequenom CMM's MaterniT21(TM) PLUS laboratory-developed test and the technology used in the test to healthcare providers and their patients via Laboratoire Cerba's network in France, Belgium, Luxembourg and portions of the Middle East and Africa. Under the terms of the license agreement, Sequenom will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France. Laboratoire Cerba will also have rights to market its noninvasive testing service in multiple countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria, Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso and Cameroun. Effective immediately, the contract term for the technology license is active through 2018.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|